{"id":"https://genegraph.clinicalgenome.org/r/cbe00f97-6cb9-41bf-82f7-baebe00d035fv1.0","type":"EvidenceStrengthAssertion","dc:description":"*TBK1* was first reported in relation to autosomal dominant amyotrophic lateral sclerosis in 2015 (Cirulli et al. Science (2015); PMID: 25700176 and Freischmidt et al. Nat Neurosci (2015); PMID: 25803835). Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found difference in molecular mechanism(s) and phenotypic variability. Therefore, the following disease entities have been split into multiple disease entities, amyotrophic lateral sclerosis (OMIM:616439) and herpes simplex virus encephalitis (OMIM:617900). A case-control genome-wide gene burden analysis of whole-exome sequencing data from 4,187 cases and 8,776 controls identified a burden of \"dominant not benign\" variants in *TBK1* among ALS cases compared to controls (PMID: 25700176). A further seven loss of function variants that have been reported in seven probands in two publications (PMIDs: 25803835, 30033073) are also included in this curation, as well as two splicing and nine missense variants publications (PMIDs: 25803835, 30033073). More evidence is available in the literature, but the maximum score for genetic evidence (12 pts.) has been reached. The mechanism of pathogenicity is reported to be loss of function. This gene-disease association is also supported by experimental evidence including protein interactions, expression studies, in vitro functional assays, cell models and an animal models (PMIDs: 25803835, 32413959, 30033073, 30939964, 33312375, 22921120, 25613900, 36201573). In summary, *TBK1* is definitively associated with autosomal dominant amyotrophic lateral sclerosis. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen ALS GCEP on the meeting date June 23, 2022 (SOP Version 9).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/cbe00f97-6cb9-41bf-82f7-baebe00d035f","GCISnapshot":"https://genegraph.clinicalgenome.org/r/509b9e29-d354-4974-96e9-e819c3fee579","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/509b9e29-d354-4974-96e9-e819c3fee579_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10096","date":"2022-11-03T16:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/509b9e29-d354-4974-96e9-e819c3fee579_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10096","date":"2022-12-29T22:08:43.191Z","role":"Publisher"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/509b9e29-d354-4974-96e9-e819c3fee579_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2190a56d-92ac-41ed-971e-81aede915989","type":"EvidenceLine","dc:description":"Absent from gnomAD non-neuro.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2190a56d-92ac-41ed-971e-81aede915989_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"A protein product was virtually absent when expressing the mutation in HEK293T cells (Fig. 3a).","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/2190a56d-92ac-41ed-971e-81aede915989_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25803835","allele":{"id":"https://genegraph.clinicalgenome.org/r/3c1122d9-b257-473e-9933-3cd0d65e889d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_013254.4(TBK1):c.1436_1437del (p.Val479GlufsTer4)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10575727"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/94a31171-20ee-4706-b9bd-6e8fcfccb793","type":"EvidenceLine","dc:description":"Absent from gnomAD non-neuro.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/94a31171-20ee-4706-b9bd-6e8fcfccb793_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30033073","allele":{"id":"https://genegraph.clinicalgenome.org/r/ecd6c2c8-6f51-49c4-8cf6-6f838caab8af","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_013254.4(TBK1):c.1180T>G (p.Tyr394Asp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA385600461"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/32b3c8f0-6e1f-4baf-bcb8-4c7db6283088","type":"EvidenceLine","dc:description":"Absent from gnomAD non-neuro.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/32b3c8f0-6e1f-4baf-bcb8-4c7db6283088_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Patient fribroblasts carrying this mutation showed a shortened RT-PCR and protein product carrying an in-frame 72-bp deletion (r.2067_2138del, p.690_713del) in exon 20 (Supplementary Figs. 4a,c and 5). PMID:25803835\nUnable to bind normal interacting partner OPTN (shown by immunoprecipitation and GST pull-down, Fig. 3a-b, Fig.S6a-b). PMID:25803835","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/32b3c8f0-6e1f-4baf-bcb8-4c7db6283088_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25803835","allele":{"id":"https://genegraph.clinicalgenome.org/r/a9af8587-169c-4dc3-b929-497a0308db38","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_013254.4(TBK1):c.2138+2T>C","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10575728"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/4697d1cc-ace5-49dd-bbee-85895a5fd5ee","type":"EvidenceLine","dc:description":"Absent from gnomAD non-neuro.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4697d1cc-ace5-49dd-bbee-85895a5fd5ee_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30033073","allele":{"id":"https://genegraph.clinicalgenome.org/r/bf0a2a6d-22d1-4cb2-a0ec-1a01b08226b9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_013254.4(TBK1):c.1694A>C (p.Gln565Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA385604648"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/c47b58e7-0c9b-4466-84d1-1dbb3e93a7de","type":"EvidenceLine","dc:description":"Absent from gnomAD non-neuro. ","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c47b58e7-0c9b-4466-84d1-1dbb3e93a7de_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"qRT-PCR of patient cell lines showed reduction of TBK1 expression by approx. 50%, and was also reflected at the protein level (Supplementary Fig. 4 and Supplementary Table 4).","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/c47b58e7-0c9b-4466-84d1-1dbb3e93a7de_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25803835","allele":{"id":"https://genegraph.clinicalgenome.org/r/0a50f2d1-b451-495b-ba8c-1e9267894d23","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_013254.4(TBK1):c.1349_1352del (p.Ile450LysfsTer15)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10575726"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/beb1b32d-8ca2-4ec7-9c76-cad1c721195b","type":"EvidenceLine","dc:description":"gnomAD non-neuro MAF = 0.00000575, greater than the ALS threshold of 0.000005.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/beb1b32d-8ca2-4ec7-9c76-cad1c721195b_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"qRT-PCR of patient cell lines showed reduction of TBK1 expression by approx. 50%, and was also reflected at the protein level (Supplementary Fig. 4 and Supplementary Table 4).","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/beb1b32d-8ca2-4ec7-9c76-cad1c721195b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25803835","allele":{"id":"https://genegraph.clinicalgenome.org/r/709fff50-c69d-491c-a989-1775ed14a82b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_013254.4(TBK1):c.1340+1G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA6669037"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/ac92cef7-0815-465c-967e-f1716ab8574a","type":"EvidenceLine","dc:description":"Absent from gnomAD non-neuro.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ac92cef7-0815-465c-967e-f1716ab8574a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30033073","allele":{"id":"https://genegraph.clinicalgenome.org/r/2ce0df97-3448-4e56-96db-3605c67e59f5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_013254.4(TBK1):c.1887_1890del (p.Gln629HisfsTer4)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2573130149"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/0ac0e293-aacb-4f4d-96ae-a42ea1c46c88","type":"EvidenceLine","dc:description":"Absent from gnomAD non-neuro.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0ac0e293-aacb-4f4d-96ae-a42ea1c46c88_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30033073","allele":{"id":"https://genegraph.clinicalgenome.org/r/d9a68785-7d2a-4fe6-a5b3-fdbaa115d188","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_013254.4(TBK1):c.649G>A (p.Gly217Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA385597745"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/7b377d9c-c7d4-42c9-a3be-be7d1f78302d","type":"EvidenceLine","dc:description":"Absent from gnomAD non-neuro.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7b377d9c-c7d4-42c9-a3be-be7d1f78302d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30033073","allele":{"id":"https://genegraph.clinicalgenome.org/r/fc2d1bf6-0100-4528-8c87-099776273816","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_013254.4(TBK1):c.64A>C (p.Asn22His)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA385593053"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/2c4197c2-4d2a-4be5-adec-eabb90ec7038","type":"EvidenceLine","dc:description":"Absent from gnomAD non-neuro.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2c4197c2-4d2a-4be5-adec-eabb90ec7038_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30033073","allele":{"id":"https://genegraph.clinicalgenome.org/r/3b4389a3-343f-407d-a8c5-adfacf985f22","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_013254.4(TBK1):c.385A>G (p.Asn129Asp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA385595855"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/feea33d9-7872-4391-b6dd-58f3f9d1f1be","type":"EvidenceLine","dc:description":"Absent from gnomAD non-neuro.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/feea33d9-7872-4391-b6dd-58f3f9d1f1be_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25803835","allele":{"id":"https://genegraph.clinicalgenome.org/r/83241c8f-abbc-4d2f-81bf-994687a87106","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_013254.4(TBK1):c.1676T>G (p.Met559Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA385604605"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/0a126aaf-6444-4edc-a1b3-242d5bb0d14d","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0a126aaf-6444-4edc-a1b3-242d5bb0d14d_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Caused loss of ability to bind OPTN shown by co-IP in HEK293T model (Fig. 3a). PMID:25803835\nCaused loss of kinase activity in HEK293T model (Fig. 3c). PMID:25803835","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/0a126aaf-6444-4edc-a1b3-242d5bb0d14d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25803835","allele":{"id":"https://genegraph.clinicalgenome.org/r/c4874dec-b00e-4d77-978a-81e3a0625499","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_013254.4(TBK1):c.923G>A (p.Arg308Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA385599320"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/509b9e29-d354-4974-96e9-e819c3fee579_cc_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c68fe58d-51db-4aef-af53-9801bb8922d1","type":"EvidenceLine","dc:description":"This genome-wide gene burden analysis identified known ALS genes (eg. SOD1) and a novel ALS gene, TBK1. A total of 4,187 cases and 8,776 controls were analysed, predominately using whole exome sequencing with a small proportion of individuals undergoing custom capture and sequencing. Cases and controls were genetically matched for ethnicity (European). A burden of \"dominant not benign\" variants was identified in TBK1 when comparing cases vs controls to implicate TBK1 as a novel ALS gene. This result provided a highly significant p-value of P = 3.60 × 10^−11, in reference to the adjusted significance threshold of p<9.07x10^-7 which accounts for multiple testing of all genes across 6 different models employed in this study.","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c68fe58d-51db-4aef-af53-9801bb8922d1_cc_evidence_item","type":"Finding","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25700176","rdfs:label":"Cirulli2015 Combined Cohort","caseCohort":{"id":"https://genegraph.clinicalgenome.org/r/10ba46df-dcac-4147-a43d-dd0f8d27eb7b","type":"Cohort","allGenotypedSequenced":4187,"alleleFrequency":0.0109863864342011,"detectionMethod":"Majority of samples underwent whole exome sequencing, however a proportion did undergo custom capture sequencing.","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c68fe58d-51db-4aef-af53-9801bb8922d1_cc_evidence_item"}],"numWithVariant":46,"relatedCondition":{"id":"obo:MONDO_0014641"}},"controlCohort":{"id":"https://genegraph.clinicalgenome.org/r/42bfd5c9-4b3d-4b8a-9521-5f45941ca5c9","type":"Cohort","allGenotypedSequenced":8776,"alleleFrequency":0.001937101185050137,"detectionMethod":"Majority of samples underwent whole exome sequencing, however a proportion did undergo custom capture sequencing","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c68fe58d-51db-4aef-af53-9801bb8922d1_cc_evidence_item"}],"numWithVariant":17},"method":{"id":"cg:AggregateVariantAnalysis"},"pValue":3.6E-11,"statisticalSignificanceType":""}],"specifiedBy":"GeneValidityCaseControlAggregateVariantAnalysisCriteria","strengthScore":5},{"id":"https://genegraph.clinicalgenome.org/r/61ec819d-7100-4ad5-8034-f11ee23f8754","type":"EvidenceLine","dc:description":"This phase of analysis did not reach the corrected significance threshold. The paper states \"The adjusted alpha after correcting for the number of genes tested over all six genetic models is p<9.07x10^-7\".","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/61ec819d-7100-4ad5-8034-f11ee23f8754_cc_evidence_item","type":"Finding","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25700176","rdfs:label":"Cirulli2015 Discovery Cohort","caseCohort":{"id":"https://genegraph.clinicalgenome.org/r/64ba10fb-efbd-435e-9e34-f78fb52a8a68","type":"Cohort","allGenotypedSequenced":2869,"alleleFrequency":0.00801673056814221,"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/61ec819d-7100-4ad5-8034-f11ee23f8754_cc_evidence_item"}],"numWithVariant":23,"relatedCondition":{"id":"obo:MONDO_0014641"}},"controlCohort":{"id":"https://genegraph.clinicalgenome.org/r/7e6f3a32-9431-4b82-b251-502506b9fd35","type":"Cohort","allGenotypedSequenced":6405,"alleleFrequency":0.001873536299765808,"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/61ec819d-7100-4ad5-8034-f11ee23f8754_cc_evidence_item"}],"numWithVariant":12},"method":{"id":"cg:AggregateVariantAnalysis"},"pValue":0.000011,"statisticalSignificanceType":"","statisticalSignificanceValue":4.3,"statisticalSignificanceValueType":"Odds Ratio"}],"specifiedBy":"GeneValidityCaseControlAggregateVariantAnalysisCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallCaseControlEvidenceCriteria","strengthScore":5},{"id":"https://genegraph.clinicalgenome.org/r/eb1c8ec5-5418-4906-99d1-92486e84fc12","type":"EvidenceLine","dc:description":"Absent from gnomAD non-neuro.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/eb1c8ec5-5418-4906-99d1-92486e84fc12_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30033073","allele":{"id":"https://genegraph.clinicalgenome.org/r/dca6aae3-1439-4007-b339-ec6b89543e90","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_013254.4(TBK1):c.1869_1875del (p.Met623IlefsTer9)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2573130148"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/509b9e29-d354-4974-96e9-e819c3fee579_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/873e264e-748d-464d-8435-f0c963bfee98_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25803835","rdfs:label":"Freischmidt2015 Family 4","family":{"id":"https://genegraph.clinicalgenome.org/r/873e264e-748d-464d-8435-f0c963bfee98","type":"Family","rdfs:label":"Freischmidt2015 Family 4","member":{"id":"https://genegraph.clinicalgenome.org/r/8c85d0e0-5340-4dc5-b3b2-c6be827e0470","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25803835","rdfs:label":"Family 4 proband","allele":{"id":"https://genegraph.clinicalgenome.org/r/3c1122d9-b257-473e-9933-3cd0d65e889d"},"firstTestingMethod":"Exome sequencing","previousTesting":true,"previousTestingDescription":"Negative screen for SOD1 and C9orf72 mutations.","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/2190a56d-92ac-41ed-971e-81aede915989_variant_evidence_item"}}},"phenotypePositiveAllelePositive":1,"proband":{"id":"https://genegraph.clinicalgenome.org/r/8c85d0e0-5340-4dc5-b3b2-c6be827e0470"}},{"id":"https://genegraph.clinicalgenome.org/r/0b7ecca8-6ef1-4b2d-96a1-fd2426bfd42a_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25803835","rdfs:label":"Freischmidt2015 Family 2","family":{"id":"https://genegraph.clinicalgenome.org/r/0b7ecca8-6ef1-4b2d-96a1-fd2426bfd42a","type":"Family","rdfs:label":"Freischmidt2015 Family 2","member":{"id":"https://genegraph.clinicalgenome.org/r/937579af-212f-4fdd-98b9-8706d99b6bab","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25803835","rdfs:label":"Freischmidt2015 Family 2 - III/6","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":77,"allele":{"id":"https://genegraph.clinicalgenome.org/r/0a50f2d1-b451-495b-ba8c-1e9267894d23"},"firstTestingMethod":"Exome sequencing","previousTesting":true,"previousTestingDescription":"Negative screen for SOD1 and C9orf72 mutations.","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/c47b58e7-0c9b-4466-84d1-1dbb3e93a7de_variant_evidence_item"}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":3,"proband":{"id":"https://genegraph.clinicalgenome.org/r/937579af-212f-4fdd-98b9-8706d99b6bab"},"publishedLodScore":1.4},{"id":"https://genegraph.clinicalgenome.org/r/23b4950a-ebb4-404c-b309-a2e6e4a34ebf_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25803835","rdfs:label":"Freischmidt2015 Family 6","family":{"id":"https://genegraph.clinicalgenome.org/r/23b4950a-ebb4-404c-b309-a2e6e4a34ebf","type":"Family","rdfs:label":"Freischmidt2015 Family 6","member":{"id":"https://genegraph.clinicalgenome.org/r/1dcf2e5f-d127-4ea0-b863-512c55b1c4e1","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25803835","rdfs:label":"Freischmidt2015 Family 6 - III/2","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":35,"allele":{"id":"https://genegraph.clinicalgenome.org/r/52304418-2f4a-4b97-980c-6f50fbe42485","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000012.12:g.64464465T>C (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA385595650"}},"firstTestingMethod":"Exome sequencing","previousTesting":true,"previousTestingDescription":"Negative screen for SOD1 and C9orf72 mutations.","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/f2477380-dff8-4d68-9bfb-49e622b66b0d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25803835","allele":{"id":"https://genegraph.clinicalgenome.org/r/52304418-2f4a-4b97-980c-6f50fbe42485"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"phenotypePositiveAllelePositive":1,"proband":{"id":"https://genegraph.clinicalgenome.org/r/1dcf2e5f-d127-4ea0-b863-512c55b1c4e1"}},{"id":"https://genegraph.clinicalgenome.org/r/5e7c412d-f373-4d60-b91d-cc8bc7497077_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25803835","rdfs:label":"Freischmidt2015 Family 1","family":{"id":"https://genegraph.clinicalgenome.org/r/5e7c412d-f373-4d60-b91d-cc8bc7497077","type":"Family","rdfs:label":"Freischmidt2015 Family 1","member":{"id":"https://genegraph.clinicalgenome.org/r/e9785091-6a45-4e6a-ab0f-1268a68dc5e2","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25803835","rdfs:label":"Freischmidt2015 Family 1 index patient","allele":{"id":"https://genegraph.clinicalgenome.org/r/b8792a48-339b-4bc1-bee4-7469236d3910","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_013254.4(TBK1):c.958del (p.Thr320fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA6668928"}},"firstTestingMethod":"Exome sequencing","previousTesting":true,"previousTestingDescription":"Negative screen for SOD1 and C9orf72 mutations.","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/8b6c03c6-aa26-4bd6-b9f7-89e6c23dce66_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25803835","allele":{"id":"https://genegraph.clinicalgenome.org/r/b8792a48-339b-4bc1-bee4-7469236d3910"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"phenotypePositiveAllelePositive":1,"proband":{"id":"https://genegraph.clinicalgenome.org/r/e9785091-6a45-4e6a-ab0f-1268a68dc5e2"}},{"id":"https://genegraph.clinicalgenome.org/r/99e89826-c007-4618-a0f2-9b26429efce0_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25803835","rdfs:label":"Freischmidt2015 Family 11+12","family":{"id":"https://genegraph.clinicalgenome.org/r/99e89826-c007-4618-a0f2-9b26429efce0","type":"Family","rdfs:label":"Freischmidt2015 Family 11+12","member":{"id":"https://genegraph.clinicalgenome.org/r/7301298b-a1a2-46ed-9f3f-fb5a29f994cc","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25803835","rdfs:label":"Freischmidt2015 Family 11 - VI/2","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":52,"allele":{"id":"https://genegraph.clinicalgenome.org/r/a9af8587-169c-4dc3-b929-497a0308db38"},"firstTestingMethod":"Exome sequencing","previousTesting":true,"previousTestingDescription":"Negative screen for SOD1 and C9orf72 mutations.","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/32b3c8f0-6e1f-4baf-bcb8-4c7db6283088_variant_evidence_item"}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":2,"proband":{"id":"https://genegraph.clinicalgenome.org/r/7301298b-a1a2-46ed-9f3f-fb5a29f994cc"},"publishedLodScore":2.6},{"id":"https://genegraph.clinicalgenome.org/r/41940158-e6ff-463c-9777-d773aba481f7_family_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25803835","rdfs:label":"Freischmidt2015 Family 5","family":{"id":"https://genegraph.clinicalgenome.org/r/41940158-e6ff-463c-9777-d773aba481f7","type":"Family","rdfs:label":"Freischmidt2015 Family 5"},"phenotypePositiveAllelePositive":2},{"id":"https://genegraph.clinicalgenome.org/r/6e8b9224-17b0-4711-b946-070b4569e48f_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25803835","rdfs:label":"Freischmidt2015 Family 7","family":{"id":"https://genegraph.clinicalgenome.org/r/6e8b9224-17b0-4711-b946-070b4569e48f","type":"Family","rdfs:label":"Freischmidt2015 Family 7","member":{"id":"https://genegraph.clinicalgenome.org/r/6ed67825-ab31-4c45-bca4-d52decdb95b3","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25803835","rdfs:label":"Freischmidt2015 Family 7 proband","allele":{"id":"https://genegraph.clinicalgenome.org/r/709fff50-c69d-491c-a989-1775ed14a82b"},"firstTestingMethod":"Exome sequencing","previousTesting":true,"previousTestingDescription":"Negative screen for SOD1 and C9orf72 mutations.","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/beb1b32d-8ca2-4ec7-9c76-cad1c721195b_variant_evidence_item"}}},"phenotypePositiveAllelePositive":1,"proband":{"id":"https://genegraph.clinicalgenome.org/r/6ed67825-ab31-4c45-bca4-d52decdb95b3"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/163625d8-b843-4462-8180-29c2794defd6","type":"EvidenceLine","dc:description":"Absent from gnomAD non-neuro.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/163625d8-b843-4462-8180-29c2794defd6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30033073","allele":{"id":"https://genegraph.clinicalgenome.org/r/eac06e39-eaef-4092-9ee6-e5f69838a194","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_013254.4(TBK1):c.4C>T (p.Gln2Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA385592734"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/04223402-a42f-4454-a33d-55217914fe58","type":"EvidenceLine","dc:description":"Absent from gnomAD non-neuro.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/04223402-a42f-4454-a33d-55217914fe58_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Caused loss of kinase activity in HEK293T model (Fig. 3c). PMID:25803835","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/04223402-a42f-4454-a33d-55217914fe58_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25803835","allele":{"id":"https://genegraph.clinicalgenome.org/r/2e46f4e4-4f6b-4ff4-8b42-8addfe71d8e9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_013254.4(TBK1):c.140G>A (p.Arg47His)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA385594429"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/f2477380-dff8-4d68-9bfb-49e622b66b0d","type":"EvidenceLine","dc:description":"Absent from gnomAD non-neuro.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f2477380-dff8-4d68-9bfb-49e622b66b0d_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"qRT-PCR of patient cell lines showed reduction of TBK1 expression by approx. 50%, and was also reflected at the protein level (Supplementary Fig. 4 and Supplementary Table 4).","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/f2477380-dff8-4d68-9bfb-49e622b66b0d_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/b85455a6-8080-4fa1-b250-4d7620f5a173","type":"EvidenceLine","dc:description":"Absent from gnomAD non-neuro.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b85455a6-8080-4fa1-b250-4d7620f5a173_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25803835","allele":{"id":"https://genegraph.clinicalgenome.org/r/54ac66c6-717c-4455-8422-10bc2551ca7d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_013254.4(TBK1):c.1712C>T (p.Ala571Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA6669132"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/2c5694e0-adbd-44de-9ff0-5f48d2eea3b4","type":"EvidenceLine","dc:description":"Predicted consequence: p.Gly272_Thr331del. Absent from gnomAD non-neuro.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2c5694e0-adbd-44de-9ff0-5f48d2eea3b4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30033073","allele":{"id":"https://genegraph.clinicalgenome.org/r/33afd08a-26e5-4a3e-a5e5-cb8b22f7db92","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_013254.4(TBK1):c.992+1G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA385599596"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/8b6c03c6-aa26-4bd6-b9f7-89e6c23dce66","type":"EvidenceLine","dc:description":"Absent from gnomAD non-neuro.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8b6c03c6-aa26-4bd6-b9f7-89e6c23dce66_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"A protein product was virtually absent when expressing the mutation in HEK293T cells (Fig. 3a).","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/8b6c03c6-aa26-4bd6-b9f7-89e6c23dce66_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/509b9e29-d354-4974-96e9-e819c3fee579_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/509b9e29-d354-4974-96e9-e819c3fee579_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6dd42649-54b7-46b3-837b-e8ddae714dd7","type":"EvidenceLine","dc:description":"Homozygous deletion does not TBK1 in this mouse model does not mirror the effects of homozygous deletion of TBK1 in humans (lethality). ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8387a4bf-d27e-41e5-ad93-2d11cf0ff6d6","type":"Finding","dc:description":"1.\tReduced (barely detectable) expression of TBK1 in TBK1-NKO mice neuronal tissues (cortex and cerebellum), mimicking the haploinsuffieceincy of TBK1 observed in ALS patient TBK1 mutation carriers.\n2.\tImpaired motor function, demonstrated by reduced swimming distance of TBK1-NKO mice, recapitulating motor impairments experienced by ALS patients, loss of the ability/reduced capacity to walk.\n3.\tALS patients display numerous neuropathological changes, including the loss/death of motor neurons, abnormally shaped neurons, presence of ubiquitinated protein inclusions in affected motor neurons, etc. Many similar features were observed in TBK1-NKO mice, namely: A) abnormally shaped neurons in the cortex Fig. 4A and Fig S1, B) decreased density of dendritic spines in the cortex and hippocampus (Fig. 4B, C and Fig. S2), C) reduced number of synapses in the cortex (Fig. 4D, E), D) Presence of protein aggregates containing ubiquitin and p62 (Fig. 5), E) increased astrocyte activation (Fig. 6A), F) glial degeneration (Fig. 6B), G) p62 aggregates in abnormal cerebellar astrocytes (Fig. 6C), H) elevated p62 expression in cerebellum and cortex (only significant in the cortex) (Fig. 7A) and I) dendritic swelling in the Purkinje cell layer\nand neurofibrillary tangles in the cortex (Fig. 8). \n\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31039129","rdfs:label":"Conditional neuron-specific Tbk1 knockout mouse model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/c35bccdb-dc02-4457-b425-b428bf9d3014","type":"EvidenceLine","dc:description":"As this is a double mutant mouse model, the score has been downgraded. However, the exacerbated phenotypes observed in the double mutant including the TBK1 mutation compared to the single mutant C9orf72 mouse model are indeed consistent with observations in the literature where patients carrying both C9orf72 and TBK1 mutations experience more severe ALS disease courses compared with patients carrying only a C9orf72 expansion.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e0dfe166-c0d8-42c8-9911-c050f09cc988","type":"Finding","dc:description":"When compared to single mutant C9orf72-(G4C2)149 mice, double mutant mice carrying both C9orf72-(G4C2)149 + TBK1-R228H showed enhanced ALS phenotypes seen in humans, namely:\n\n1. Motor impairments: progressive hindlimb clasping defect (Fig. 3A) and showed impaired performance in the rotarod (fig. S3A), hanging wire (Fig.3B), and fear conditioning tests (fig. S3B). Reflecting the various motor difficulties experienced by ALS patients.\n\n2. Pathological post mortem brain features: reduced total brain weight (Fig. 3C), cortical neuronal loss and a noticeably thinner cortex (Fig. 3, D and E). Both of which are observed in ALS patient post mortem tissues. \n\n3. Increased neuroinflammation: increased the expression of the microglial markers Iba1 (fig. S4A) andCD68 (fig. S4B)and the astroglial marker GFAP(fig. S4C). \n\n4. Neuronal inclusions: increased number of inclusions in neurons (Fig. 3,G and I, Fig S4). Particularly there was an increased number of pTDP-43 positive inclusions (Fig. 4, E and F). The hallmark feature of ALS patients is the presence of protein inclusions within motor neurons, and these contain TDP-43 in ~97% of ALS patients.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36201573","rdfs:label":"C9orf72-(G4C2)149 + TBK1 R228H mouse model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/b729860a-9071-444a-85fd-e7ef9da7aafc","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/04a715a6-a584-4771-8a8c-f4ed17a0ec9c","type":"Finding","dc:description":"\"Reduction of TBK1 protein levels - Haploinsufficiency of TBK1 has been demonstrated in TBK1 mutation carrier ALS patients, thus a ~50% reduction of TBK1 protein levels in the model mimics this phenotype.\n\nMotor neuron death - Death of upper and lower motor neurons is a defining characteristic of ALS, therefore a progressive reduction in the number of motor neurons seen in this model mimics this phenotype.\n\nProtein aggregate accumulation - Misfolded protein aggregates within affected motor neurons are a hallmark feature of ALS, therefore the presence of such aggregates in this model mimics this phenotype.\"","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30939964","rdfs:label":"hiPSC-derived motor neuron model of TBK1 mutants","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityCellCultureModelOrganismCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/c183bea7-bd48-45df-ade6-3dd35b433038","type":"EvidenceLine","dc:description":"Score downgraded from default 1 to 0.5 as phenotypes are very basic and not particularly ALS-specific, and only one variant has been modelled.\n","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3c4479a8-0940-4b47-9126-1b9a20386571","type":"Finding","dc:description":"Loss of motor neurons is a hallmark feature observed in ALS patient postmortem neuronal tissues, the model recapitulates this by showing 1) decreased cell viability showed by CCK-8 assay and 2) decreased cell proliferation measured by Ki67 staining\n\nIncreased level of relative reactive oxygen species measured by Flow Cytometry\nIncreased expression of p62 by Western Blot\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33312375","rdfs:label":"hTBK1-c.978T>A NSC-34 cell culture model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityCellCultureModelOrganismCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/509b9e29-d354-4974-96e9-e819c3fee579_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/21ef8d00-1543-496d-901a-9b954d914de9","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e2a300dc-1bb1-4252-8cf8-13b4833ac5ab","type":"FunctionalAlteration","dc:description":"Western blot analysis of 5 patient lymphoblastoid cell lines carrying 5 different TBK1 mutations showed lower levels of phosphorylated TBK1 compared to 7 controls lymphoblastoid cell lines. This difference was quantitated using an unpaired 2 tailed t-test (p=0.0229).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30033073","rdfs:label":"TBK1 mutant lymphoblastoids show reduced TBK1phosphorylation"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/49e79eea-394d-4c5f-9d28-976c351504f1","type":"EvidenceLine","dc:description":"Four distinct functional alterations have been demonstrated for two different mutations, thus have increased to a maximum score of 1.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5ca45349-70f8-422f-a9d5-0b897ed7b677","type":"FunctionalAlteration","dc:description":"1. Decreased phosphorylation of the substrate IRF3.\nWestern blot showing reduced levels of phosphorylated IRF3 for the mutants compared to WT, confirmed using immunocytochemistry.\n\n2. Decreased binding to, and phosphorylation of, OPTN. \nCo-IP with HA-tag pull down of TBK1 showing no binding of OPTN for mutants compared to WT. transiently cotransfected HEK293T treated with alkaline phosphatase and analyzed by Western blot showed a lack of OPTN phosphorylation in mutated samples. \n\n3. Decrease the phosphorylation of TBK1 itself.\nWestern blot showing reduced levels of phosphorylated TBK1 for the mutants compared to WT, confirmed using immunocytochemistry.\n\n4. Disruption of TBK1 homodimerization. \nNative gel analysis of transiently cotransfected HEK293T cells showed  weaker dimer and monomer for G217R. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30033073","rdfs:label":"TBK1 mutant transfected HEK293T cells functional alterations"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/509b9e29-d354-4974-96e9-e819c3fee579_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8532914d-bdd3-4b69-853c-b239e974a621","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e30f78d9-4bba-473d-9423-6dd6f91fdf35","type":"Finding","dc:description":"Numerous mutations in UBQLN2 have been implicated a cause of ALS, this disease-gene relationship has been curated and classed as \"definitive\" by the ClinGen ALS GCEP. \n\nTBK1 and OPTN have been demonstrated as protein interacting partners through both 1) immunoprecipitation of TBK1-myc and UBLN2-Flag, in both directions and 2) GST pull-down where His-UBQLN2 was effectively pulled down with GST-TBK1.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32413959","rdfs:label":"TBK1 interacts with the ALS protein UBQLN2","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/ea64eed3-3b37-4f10-abb2-0475659e1a02","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/937d0027-7e94-413d-a8ca-1abfa27ef2ae","type":"Finding","dc:description":"Numerous mutations in OPTN have been implicated a cause of ALS, this disease-gene relationship has been curated and classed as \"definitive\" by the ClinGen ALS GCEP.\n\nTBK1 and OPTN have been demonstrated as protein interacting partners through both 1) Co-immunoprecipitation (Co-IP) of EGFP-OPTN and Flag–wild-type TBK1 and 2) GST pull-down of TBK1 transfected HEK293T cell lysates incubated with recombinant, immobilized GST-OPTN.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25803835","rdfs:label":"TBK1 interacts with the ALS protein OPTN","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/948e1490-48d5-40c6-a52c-8cea293b9825","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/72d991b3-30c3-4296-9e5a-2ce3f71d912f","type":"Finding","dc:description":"This paper demonstrates that TBK1 phosphorylates SQSTM1 (p62).\n\nVarious experiments were used to demonstrate this relationship, and the sum of their results provides robust evidence of this interaction. This includes:\n1) Intracellular co-localisation analysis of TBK1 and p62/SQSTM1  in murine bone marrow macrophages showed that the two proteins co-localise\n2) Murine bone marrow macrophages treated with a TBK1 inhibitor showed an increase in p62 puncta via high-content quantitative imaging analysis and a endogenous p62 antibody - confirmed by Western Blot.\n3) p62 was shown to accumulate in TBK1 -/- cells, suggesting TBK1 is necessary for p62 autophagic degradation\n4) Showed that TBK1 phosphorylates p62 using:\na. co-expression in HEK293 cells, immunoprecipitation of p62 and mass spectrometry\nb. HEK293 cells transfected with TBK1, treated or untreated with a TBK1 inhibitor, and immunoblotted with a phosphospecific antibody\nc. E.coli MBP and MBP-p62 proteins expressed and purified from E.coli, and purified proteins were incubated with active TBK-1 in the presence of [γ-32P] ATP for 10 min at 30°C. The reaction products were analysed by autoradiography","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22921120","rdfs:label":"TBK1 phosphorylates p62/SQSTM1","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/f81e60d3-5063-4366-9da9-9d724af76111","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1852e982-6ffa-4ff7-a6de-62ac5639eb85","type":"Finding","dc:description":"Genome-wide integrated omics approach involving quantitative transcriptomics at the tissue and organ level (RNA-seq), combined with tissue microarray–based immunohistochemistry (tiussue microarrays) demonstrated expression of TBK1 in the brain at both the RNA and protein levels.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25613900","rdfs:label":"Tissue-based map of the human proteome","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Definitive","sequence":5591,"specifiedBy":"GeneValidityCriteria9","strengthScore":18,"subject":{"id":"https://genegraph.clinicalgenome.org/r/sfGQqnwUWNo","type":"GeneValidityProposition","disease":"obo:MONDO_0014641","gene":"hgnc:11584","modeOfInheritance":"obo:HP_0000006"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_509b9e29-d354-4974-96e9-e819c3fee579-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}